Heart Transplant Failure Clinical Trial
Official title:
Levothyroxine Supplementation for Heart Transplant Recipients: A Randomized Control Trial
This will be a prospective, randomized study performed at a single tertiary referral academic medical center (University of California San Francisco, CA), evaluating the survival benefits of levothyroxine compared with no levothyroxine for patients who have undergone heart transplant. It will be double-blinded and placebo-control; participants will be randomized to receive levothyroxine or receive no levothyroxine.
Studies have shown that thyroid hormone results in a higher number of organs available for transplant. Increasingly, thyroid hormone supplementation is used amongst transplant donors. However, it is not the current standard of practice to supplement recipients without a prior medical history of hypothyroidism with levothyroxine. Two large retrospective studies have demonstrated improved 30-days survival and lower risk of all-cause mortality for heart transplant recipients who receive levothyroxine in the post-operative context. No randomized trials have tested this hypothesis and so the investigators aim to trial the use of levothyroxine for heart transplant recipients at University of California San Francisco using a double-blinded and placebo controlled randomized control trial study design. This will be a prospective, randomized study performed at a single tertiary referral academic medical center (University of California San Francisco, CA), evaluating the survival benefits of levothyroxine compared with no levothyroxine for patients who have undergone heart transplant. It will be double-blinded and placebo-control; participants will be randomized to receive levothyroxine or receive no levothyroxine. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04508907 -
A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients
|
Phase 4 | |
| Active, not recruiting |
NCT04904614 -
Letermovir Use in Heart Transplant Recipients
|
Phase 4 | |
| Active, not recruiting |
NCT05064462 -
TTV Viral Load in Heart Transplant Recipients
|
||
| Active, not recruiting |
NCT03924219 -
CMV T Cell Immunity in Pediatric Solid Organ Transplant Recipients
|
||
| Recruiting |
NCT04278547 -
Multicenter Clinical Trial to Evaluate the Efficacy of a Preventive Strategy Against CMV Infection in Heart Transplant Patients, Based on the Specific T Cells Response
|
Phase 4 | |
| Recruiting |
NCT06464016 -
Complications in Pediatric Mechanical Circulatory Assistance: Evaluation of Infection Management.
|
||
| Active, not recruiting |
NCT03386539 -
Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score
|
Phase 3 | |
| Recruiting |
NCT04017338 -
Transplantation Using Hepatitis C Positive Donors, A Safety Trial
|
Phase 3 |